Can I Take Turmeric / Curcumin with PT-141 (Bremelanotide)?
At a glance
- Approved product / Vyleesi (bremelanotide) 1.75 mg subcutaneous autoinjector, prescription only [1]
- Approved use / Premenopausal women with acquired, generalized HSDD; not indicated in men or postmenopausal women [1]
- Direct answer / The Vyleesi drug interactions section names naltrexone and oral medicines in general, not turmeric or curcumin [1]
- Bremelanotide metabolism / Hydrolysis of amide bonds; mean half-life about 2.7 hours [1]
- Curcumin probe-drug study / 8 volunteers, 4 g curcuminoids plus 24 mg piperine: no meaningful change in midazolam, flurbiprofen or paracetamol kinetics [2]
- Bleeding evidence / Rat and laboratory data only [3][4]
- Documented turmeric risk / Rare but serious liver injury, including one death from acute liver failure in a 10-case US series [5]
- Label interactions / Avoid oral naltrexone for addiction; slowed gastric emptying can reduce absorption of oral medicines [1]
What is known about taking the two together?
Turmeric and curcumin supplements are sold over the counter, and a Drugs@FDA search returned no approved drug application listing curcumin as an active ingredient [6]. Bremelanotide is prescription only and FDA-approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder [1]. The label does not address turmeric or curcumin, and the human curcumin interaction studies did not test bremelanotide.
Two concerns get raised: curcumin slowing the breakdown of a drug, and additive bleeding or bruising. Neither is supported by human data for this pair.
Does curcumin change how bremelanotide is metabolized?
After a 1.75 mg subcutaneous dose, bremelanotide reaches a mean Cmax of 72.8 ng/mL at a median of about 1 hour, has a mean terminal half-life of about 2.7 hours and an absolute bioavailability of about 100%; it is metabolized by hydrolysis of amide bonds, with 64.8% of radioactivity recovered in urine and 22.8% in feces [1].
Laboratory work had predicted that curcuminoids and piperine could inhibit CYP3A, CYP2C9, UGT and SULT drug metabolism. In a randomized, placebo-controlled six-way crossover, 8 healthy volunteers took a standardized curcuminoid/piperine preparation (4 g curcuminoids plus 24 mg piperine) four times over 2 days. There were no meaningful changes in Cmax, AUC, clearance, half-life or metabolite levels of midazolam (CYP3A), flurbiprofen (CYP2C9) or paracetamol (UGT and SULT), and no change in midazolam sedation or EEG effects [2]. Unconjugated curcuminoid concentrations in plasma stayed below assay detection [2]. That was short-term use in a small study, and bremelanotide was not one of the drugs tested.
What about bleeding and bruising at the injection site?
In the pooled phase 3 trials of 1,247 premenopausal women, injection site reactions, a category that includes pain, erythema, hematoma, hemorrhage, bruising and pruritus, occurred in 13.2% of Vyleesi patients versus 8.4% on placebo [1].
Laboratory studies suggest curcumin can inhibit platelet aggregation, but no human bleeding-outcome trial was found [3][4]. In rats, curcumin 100 mg/kg for 7 days raised warfarin AUC about 1.6-fold and the AUC of clopidogrel's carboxylic acid metabolite about 1.61-fold, yet prothrombin time and maximum platelet aggregation did not change [3]. A 2017 review of curcuminoid-drug interactions concluded that the in vitro and animal data are not enough to judge clinical interactions and advised caution [4]. The bleeding concern is therefore theoretical.
What does the Vyleesi label say that applies here?
The label says Vyleesi may slow gastric emptying and reduce the rate and extent of absorption of oral medicines. It says to avoid Vyleesi with oral drugs that depend on threshold blood concentrations, such as antibiotics, and to consider discontinuing Vyleesi if a delayed effect of an oral medicine is a problem when quick onset is wanted, such as indomethacin for pain relief [1]. It also says Vyleesi may significantly decrease exposure to oral naltrexone and to avoid the combination when naltrexone is used for alcohol or opioid addiction, because of the severe consequence of treatment failure [1]. In clinical pharmacology studies only naltrexone and indomethacin were meaningfully affected [1]. Turmeric and curcumin are not named in that section [1].
Is liver risk a bigger question than interaction risk?
Turmeric has the better-documented liver signal. In the US Drug-Induced Liver Injury Network series, 10 adjudicated turmeric cases were enrolled between 2004 and 2022, all since 2011 and six since 2017: 8 were women, median age 56 (range 35 to 71), injury was hepatocellular in 9 and mixed in 1, 5 were hospitalized and 1 died of acute liver failure [5]. Seven of the 10 patients carried HLA-B*35:01 (allele frequency 0.450 versus 0.056 to 0.069 in controls), and 3 of the 7 products tested also contained piperine [5]. Italian researchers described seven Tuscan hepatitis cases, all associated with high-bioavailability, high-dose curcumin products, and identified 23 additional published cases [7]. The 2026 USP expert review recommends a label caution about rarely reported liver problems and about use in people with liver disease [8].
The Vyleesi label reports a single case of acute hepatitis in the open-label extension, after 10 doses over a year, with transaminases above 40 times the upper limit of normal; liver tests returned to normal 4 months after the drug was stopped, and because another cause was not identified a role for Vyleesi could not be excluded. The label also states there was no imbalance between treatment groups in transaminase outliers or other hepatotoxicity signals in the clinical program [1]. No study has looked at liver risk when the two are used together.
Is there a set interval between turmeric and an injection?
The label's timing rules concern bremelanotide itself: 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours, and no more than 8 doses a month, with the duration of effect after a dose unknown [1].
Curcumin is poorly absorbed because it is rapidly metabolized in the liver and intestinal wall, and after oral intake plasma curcuminoids are mostly conjugated, with free curcumin often below assay detection limits [2][9]. Formulations differ widely: in a 24-person fasting crossover, a proprietary 250 mg curcumin formulation reached 101 times the Cmax and 99 times the AUC of 1,900 mg of 95% turmeric extract [10]. That study did not address timing relative to any other drug.
Does the piperine in curcumin products change anything?
Piperine, the black pepper extract added to many curcumin products, changes the levels of some oral drugs on its own. Twenty milligrams daily for 7 days raised propranolol (40 mg) and theophylline (150 mg) exposure in 6 healthy volunteers per group [11], and 20 mg raised steady-state phenytoin AUC over 12 hours and Cmax in 20 people with epilepsy taking 150 to 200 mg twice daily [12]. Its effect on bremelanotide has not been tested.
Piperine's effect on curcumin itself is disputed. A small 1998 study reported a 2000% increase in curcumin bioavailability with 20 mg piperine [9], while a later study found free curcuminoids below detection even with piperine, and the 2026 USP review reports that typical 5 to 20 mg piperine doses did not meaningfully change free or total curcuminoid levels in independent analyses [2][8].
Is PT-141 the same as Vyleesi?
Vyleesi is the FDA-approved bremelanotide product (NDA 210557, approved June 21, 2019) [1][13]. PT-141 products sold as compounded or research-use peptides are not Vyleesi and are not FDA-approved drugs, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [14][1]. The label facts above describe Vyleesi.
Frequently asked questions
Can I take turmeric or curcumin with PT-141 (bremelanotide)?
Does curcumin raise bremelanotide blood levels?
Does turmeric increase bleeding or bruising after a Vyleesi injection?
Does the piperine in curcumin supplements matter?
Is there a set wait between a curcumin dose and a PT-141 injection?
Is turmeric a liver risk alongside Vyleesi?
References
Show all 14 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- Volak LP, Hanley MJ, Masse G, Hazarika S, Harmatz JS, Badmaev V, et al. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2013;75(2):450-62.
- Liu AC, Zhao LX, Lou HX. Curcumin alters the pharmacokinetics of warfarin and clopidogrel in Wistar rats but has no effect on anticoagulation or antiplatelet aggregation. Planta Med. 2013;79(11):971-7.
- Bahramsoltani R, Rahimi R, Farzaei MH. Pharmacokinetic interactions of curcuminoids with conventional drugs: A review. J Ethnopharmacol. 2017;209:1-12.
- Halegoua-DeMarzio D, Navarro V, Ahmad J, Avula B, Barnhart H, Barritt AS, et al. Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. Am J Med. 2023;136(2):200-206.
- Drugs@FDA: FDA-Approved Drugs.
- Lombardi N, Crescioli G, Maggini V, Ippoliti I, Menniti-Ippolito F, Gallo E, et al. Acute liver injury following turmeric use in Tuscany: An analysis of the Italian Phytovigilance database and systematic review of case reports. Br J Clin Pharmacol. 2021;87(3):741-753.
- Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP - PMC.
- Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353-6.
- Kothaplly S, Alukapally S, Nagula N, Maddela R. Superior Bioavailability of a Novel Curcumin Formulation in Healthy Humans Under Fasting Conditions. Adv Ther. 2022;39(5):2128-2138.
- Bano G, Raina RK, Zutshi U, Bedi KL, Johri RK, Sharma SC. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol. 1991;41(6):615-7.
- Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother Res. 2006;20(8):683-6.
- U.S. Food and Drug Administration.
- Official web page.